ProCE Banner Activity

CASTOR: Daratumumab Added to Bortezomib/Dexamethasone Improves PFS, Response in RR Myeloma

Slideset Download
Conference Coverage
The investigators of this randomized phase III trial suggest that adding daratumumab to bortezomib/dexamethasone should be considered as a new standard of care for patients with relapsed/refractory multiple myeloma.

Released: June 08, 2016

Expiration: June 07, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals